| Analysis | Samples | Factors | Units |
|---|---|---|---|
| Reversed phase NEGATIVE ION MODE | MXP500L-0-5711_1036867631_10_1_1_1_00_1036866394_12_R28V3 | Sample material:Plasma | Treatment:after_Aspirin | Sex:F | µM |
| Reversed phase NEGATIVE ION MODE | MXP500L-0-5711_1036867631_19_1_1_1_00_1036866439_16_R30V3 | Sample material:Plasma | Treatment:after_Aspirin | Sex:F | µM |
| Reversed phase NEGATIVE ION MODE | MXP500L-0-5711_1036867631_71_1_1_1_00_1036867050_3_R22V3 | Sample material:Plasma | Treatment:after_Aspirin | Sex:F | µM |
| Reversed phase NEGATIVE ION MODE | MXP500L-0-5711_1036867631_89_1_1_1_00_1036867083_6_R24V3 | Sample material:Plasma | Treatment:after_Aspirin | Sex:F | µM |
| Reversed phase NEGATIVE ION MODE | MXP500L-0-5711_1036867631_40_1_1_1_00_1036867113_9_R26V3 | Sample material:Plasma | Treatment:after_Aspirin | Sex:M | µM |
| Reversed phase NEGATIVE ION MODE | MXP500L-0-5711_1036867631_60_1_1_1_00_1036866410_14_R29V3 | Sample material:Plasma | Treatment:after_Aspirin | Sex:M | µM |
| Reversed phase NEGATIVE ION MODE | MXP500L-0-5711_1036867631_42_1_1_1_00_1036867079_5_R24V2 | Sample material:Plasma | Treatment:before_Aspirin | Sex:F | µM |
| Reversed phase NEGATIVE ION MODE | MXP500L-0-5711_1036867631_52_1_1_1_00_1036866424_15_R30V2 | Sample material:Plasma | Treatment:before_Aspirin | Sex:F | µM |
| Reversed phase NEGATIVE ION MODE | MXP500L-0-5711_1036867631_66_1_1_1_00_1036867045_2_R22V2 | Sample material:Plasma | Treatment:before_Aspirin | Sex:F | µM |
| Reversed phase NEGATIVE ION MODE | MXP500L-0-5711_1036867631_72_1_1_1_00_1036866380_11_R28V2 | Sample material:Plasma | Treatment:before_Aspirin | Sex:F | µM |
| Reversed phase NEGATIVE ION MODE | MXP500L-0-5711_1036867631_46_1_1_1_00_1036866405_13_R29V2 | Sample material:Plasma | Treatment:before_Aspirin | Sex:M | µM |
| Reversed phase NEGATIVE ION MODE | MXP500L-0-5711_1036867631_94_1_1_1_00_1036867109_8_R26V2 | Sample material:Plasma | Treatment:before_Aspirin | Sex:M | µM |
| Reversed phase NEGATIVE ION MODE | MXP500L-0-5711_1036867631_42_1_1_1_00_1036867079_5_D2 | Sample material:Plasma | Treatment:Plasma | Sex:F | µM |
| Reversed phase NEGATIVE ION MODE | MXP500L-0-5711_1036867631_52_1_1_1_00_1036866424_15_D6 | Sample material:Plasma | Treatment:Plasma | Sex:F | µM |
| Reversed phase NEGATIVE ION MODE | MXP500L-0-5711_1036867631_66_1_1_1_00_1036867045_2_D1 | Sample material:Plasma | Treatment:Plasma | Sex:F | µM |
| Reversed phase NEGATIVE ION MODE | MXP500L-0-5711_1036867631_72_1_1_1_00_1036866380_11_D4 | Sample material:Plasma | Treatment:Plasma | Sex:F | µM |
| Reversed phase NEGATIVE ION MODE | MXP500L-0-5711_1036867631_46_1_1_1_00_1036866405_13_D5 | Sample material:Plasma | Treatment:Plasma | Sex:M | µM |
| Reversed phase NEGATIVE ION MODE | MXP500L-0-5711_1036867631_67_1_1_1_00_1036867128_10_D3 | Sample material:Plasma | Treatment:Plasma | Sex:M | µM |
| Reversed phase NEGATIVE ION MODE | MXP500L-0-5711_1036867631_17_1_1_1_00_1036865856_34_R30V3 | Sample material:Serum | Treatment:after_Aspirin | Sex:F | µM |
| Reversed phase NEGATIVE ION MODE | MXP500L-0-5711_1036867631_30_1_1_1_00_1036866481_21_R22V3 | Sample material:Serum | Treatment:after_Aspirin | Sex:F | µM |
| Reversed phase NEGATIVE ION MODE | MXP500L-0-5711_1036867631_45_1_1_1_00_1036865818_30_R28V3 | Sample material:Serum | Treatment:after_Aspirin | Sex:F | µM |
| Reversed phase NEGATIVE ION MODE | MXP500L-0-5711_1036867631_58_1_1_1_00_1036866511_24_R24V3 | Sample material:Serum | Treatment:after_Aspirin | Sex:F | µM |
| Reversed phase NEGATIVE ION MODE | MXP500L-0-5711_1036867631_06_1_1_1_00_1036866545_27_R26V3 | Sample material:Serum | Treatment:after_Aspirin | Sex:M | µM |
| Reversed phase NEGATIVE ION MODE | MXP500L-0-5711_1036867631_33_1_1_1_00_1036865837_32_R29V3 | Sample material:Serum | Treatment:after_Aspirin | Sex:M | µM |
| Reversed phase NEGATIVE ION MODE | MXP500L-0-5711_1036867631_05_1_1_1_00_1036865841_33_R30V2 | Sample material:Serum | Treatment:before_Aspirin | Sex:F | µM |
| Reversed phase NEGATIVE ION MODE | MXP500L-0-5711_1036867631_48_1_1_1_00_1036866507_23_R24V2 | Sample material:Serum | Treatment:before_Aspirin | Sex:F | µM |
| Reversed phase NEGATIVE ION MODE | MXP500L-0-5711_1036867631_82_1_1_1_00_1036866477_20_R22V2 | Sample material:Serum | Treatment:before_Aspirin | Sex:F | µM |
| Reversed phase NEGATIVE ION MODE | MXP500L-0-5711_1036867631_93_1_1_1_00_1036866564_29_R28V2 | Sample material:Serum | Treatment:before_Aspirin | Sex:F | µM |
| Reversed phase NEGATIVE ION MODE | MXP500L-0-5711_1036867631_24_1_1_1_00_1036865822_31_R29V2 | Sample material:Serum | Treatment:before_Aspirin | Sex:M | µM |
| Reversed phase NEGATIVE ION MODE | MXP500L-0-5711_1036867631_95_1_1_1_00_1036866531_26_R26V2 | Sample material:Serum | Treatment:before_Aspirin | Sex:M | µM |
| Reversed phase NEGATIVE ION MODE | MXP500L-0-5711_1036867631_05_1_1_1_00_1036865841_33_D6 | Sample material:Serum | Treatment:Serum | Sex:F | µM |
| Reversed phase NEGATIVE ION MODE | MXP500L-0-5711_1036867631_48_1_1_1_00_1036866507_23_D2 | Sample material:Serum | Treatment:Serum | Sex:F | µM |
| Reversed phase NEGATIVE ION MODE | MXP500L-0-5711_1036867631_82_1_1_1_00_1036866477_20_D1 | Sample material:Serum | Treatment:Serum | Sex:F | µM |
| Reversed phase NEGATIVE ION MODE | MXP500L-0-5711_1036867631_93_1_1_1_00_1036866564_29_D4 | Sample material:Serum | Treatment:Serum | Sex:F | µM |
| Reversed phase NEGATIVE ION MODE | MXP500L-0-5711_1036867631_07_1_1_1_00_1036866550_28_D3 | Sample material:Serum | Treatment:Serum | Sex:M | µM |
| Reversed phase NEGATIVE ION MODE | MXP500L-0-5711_1036867631_24_1_1_1_00_1036865822_31_D5 | Sample material:Serum | Treatment:Serum | Sex:M | µM |
| Reversed phase POSITIVE ION MODE | MXP500L-0-5711_1036867631_10_0_1_1_00_1036866394_12_R28V3 | Sample material:Plasma | Treatment:after_Aspirin | Sex:F | µM |
| Reversed phase POSITIVE ION MODE | MXP500L-0-5711_1036867631_19_0_1_1_00_1036866439_16_R30V3 | Sample material:Plasma | Treatment:after_Aspirin | Sex:F | µM |
| Reversed phase POSITIVE ION MODE | MXP500L-0-5711_1036867631_71_0_1_1_00_1036867050_3_R22V3 | Sample material:Plasma | Treatment:after_Aspirin | Sex:F | µM |
| Reversed phase POSITIVE ION MODE | MXP500L-0-5711_1036867631_89_0_1_1_00_1036867083_6_R24V3 | Sample material:Plasma | Treatment:after_Aspirin | Sex:F | µM |
| Reversed phase POSITIVE ION MODE | MXP500L-0-5711_1036867631_40_0_1_1_00_1036867113_9_R26V3 | Sample material:Plasma | Treatment:after_Aspirin | Sex:M | µM |
| Reversed phase POSITIVE ION MODE | MXP500L-0-5711_1036867631_60_0_1_1_00_1036866410_14_R29V3 | Sample material:Plasma | Treatment:after_Aspirin | Sex:M | µM |
| Reversed phase POSITIVE ION MODE | MXP500L-0-5711_1036867631_42_0_1_1_00_1036867079_5_R24V2 | Sample material:Plasma | Treatment:before_Aspirin | Sex:F | µM |
| Reversed phase POSITIVE ION MODE | MXP500L-0-5711_1036867631_52_0_1_1_00_1036866424_15_R30V2 | Sample material:Plasma | Treatment:before_Aspirin | Sex:F | µM |
| Reversed phase POSITIVE ION MODE | MXP500L-0-5711_1036867631_66_0_1_1_00_1036867045_2_R22V2 | Sample material:Plasma | Treatment:before_Aspirin | Sex:F | µM |
| Reversed phase POSITIVE ION MODE | MXP500L-0-5711_1036867631_72_0_1_1_00_1036866380_11_R28V2 | Sample material:Plasma | Treatment:before_Aspirin | Sex:F | µM |
| Reversed phase POSITIVE ION MODE | MXP500L-0-5711_1036867631_46_0_1_1_00_1036866405_13_R29V2 | Sample material:Plasma | Treatment:before_Aspirin | Sex:M | µM |
| Reversed phase POSITIVE ION MODE | MXP500L-0-5711_1036867631_94_0_1_1_00_1036867109_8_R26V2 | Sample material:Plasma | Treatment:before_Aspirin | Sex:M | µM |
| Reversed phase POSITIVE ION MODE | MXP500L-0-5711_1036867631_42_0_1_1_00_1036867079_5_D2 | Sample material:Plasma | Treatment:Plasma | Sex:F | µM |
| Reversed phase POSITIVE ION MODE | MXP500L-0-5711_1036867631_52_0_1_1_00_1036866424_15_D6 | Sample material:Plasma | Treatment:Plasma | Sex:F | µM |
| Reversed phase POSITIVE ION MODE | MXP500L-0-5711_1036867631_66_0_1_1_00_1036867045_2_D1 | Sample material:Plasma | Treatment:Plasma | Sex:F | µM |
| Reversed phase POSITIVE ION MODE | MXP500L-0-5711_1036867631_72_0_1_1_00_1036866380_11_D4 | Sample material:Plasma | Treatment:Plasma | Sex:F | µM |
| Reversed phase POSITIVE ION MODE | MXP500L-0-5711_1036867631_46_0_1_1_00_1036866405_13_D5 | Sample material:Plasma | Treatment:Plasma | Sex:M | µM |
| Reversed phase POSITIVE ION MODE | MXP500L-0-5711_1036867631_67_0_1_1_00_1036867128_10_D3 | Sample material:Plasma | Treatment:Plasma | Sex:M | µM |
| Reversed phase POSITIVE ION MODE | MXP500L-0-5711_1036867631_17_0_1_1_00_1036865856_34_R30V3 | Sample material:Serum | Treatment:after_Aspirin | Sex:F | µM |
| Reversed phase POSITIVE ION MODE | MXP500L-0-5711_1036867631_30_0_1_1_00_1036866481_21_R22V3 | Sample material:Serum | Treatment:after_Aspirin | Sex:F | µM |
| Reversed phase POSITIVE ION MODE | MXP500L-0-5711_1036867631_45_0_1_1_00_1036865818_30_R28V3 | Sample material:Serum | Treatment:after_Aspirin | Sex:F | µM |
| Reversed phase POSITIVE ION MODE | MXP500L-0-5711_1036867631_58_0_1_1_00_1036866511_24_R24V3 | Sample material:Serum | Treatment:after_Aspirin | Sex:F | µM |
| Reversed phase POSITIVE ION MODE | MXP500L-0-5711_1036867631_06_0_1_1_00_1036866545_27_R26V3 | Sample material:Serum | Treatment:after_Aspirin | Sex:M | µM |
| Reversed phase POSITIVE ION MODE | MXP500L-0-5711_1036867631_33_0_1_1_00_1036865837_32_R29V3 | Sample material:Serum | Treatment:after_Aspirin | Sex:M | µM |
| Reversed phase POSITIVE ION MODE | MXP500L-0-5711_1036867631_05_0_1_1_00_1036865841_33_R30V2 | Sample material:Serum | Treatment:before_Aspirin | Sex:F | µM |
| Reversed phase POSITIVE ION MODE | MXP500L-0-5711_1036867631_48_0_1_1_00_1036866507_23_R24V2 | Sample material:Serum | Treatment:before_Aspirin | Sex:F | µM |
| Reversed phase POSITIVE ION MODE | MXP500L-0-5711_1036867631_82_0_1_1_00_1036866477_20_R22V2 | Sample material:Serum | Treatment:before_Aspirin | Sex:F | µM |
| Reversed phase POSITIVE ION MODE | MXP500L-0-5711_1036867631_93_0_1_1_00_1036866564_29_R28V2 | Sample material:Serum | Treatment:before_Aspirin | Sex:F | µM |
| Reversed phase POSITIVE ION MODE | MXP500L-0-5711_1036867631_24_0_1_1_00_1036865822_31_R29V2 | Sample material:Serum | Treatment:before_Aspirin | Sex:M | µM |
| Reversed phase POSITIVE ION MODE | MXP500L-0-5711_1036867631_95_0_1_1_00_1036866531_26_R26V2 | Sample material:Serum | Treatment:before_Aspirin | Sex:M | µM |
| Reversed phase POSITIVE ION MODE | MXP500L-0-5711_1036867631_05_0_1_1_00_1036865841_33_D6 | Sample material:Serum | Treatment:Serum | Sex:F | µM |
| Reversed phase POSITIVE ION MODE | MXP500L-0-5711_1036867631_48_0_1_1_00_1036866507_23_D2 | Sample material:Serum | Treatment:Serum | Sex:F | µM |
| Reversed phase POSITIVE ION MODE | MXP500L-0-5711_1036867631_82_0_1_1_00_1036866477_20_D1 | Sample material:Serum | Treatment:Serum | Sex:F | µM |
| Reversed phase POSITIVE ION MODE | MXP500L-0-5711_1036867631_93_0_1_1_00_1036866564_29_D4 | Sample material:Serum | Treatment:Serum | Sex:F | µM |
| Reversed phase POSITIVE ION MODE | MXP500L-0-5711_1036867631_07_0_1_1_00_1036866550_28_D3 | Sample material:Serum | Treatment:Serum | Sex:M | µM |
| Reversed phase POSITIVE ION MODE | MXP500L-0-5711_1036867631_24_0_1_1_00_1036865822_31_D5 | Sample material:Serum | Treatment:Serum | Sex:M | µM |
Return to study ST003069 main page
Download data matrix(Plasma instead of serum avoids critical confounding of clinical metabolomics studies by platelets (Part 3/3 - Plasma and serum metabolomics) Reversed phase NEGATIVE ION MODE)
Download data matrix(Plasma instead of serum avoids critical confounding of clinical metabolomics studies by platelets (Part 3/3 - Plasma and serum metabolomics) Reversed phase POSITIVE ION MODE)
- Metabolomics Workbench
|